
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance
Find the latest Cognition Therapeutics, Inc. (CGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cognition Therapeutics, Inc. (CGTX) Latest Stock News & Headlines ...
Get the latest Cognition Therapeutics, Inc. (CGTX) stock news and headlines to help you in your trading and investing decisions.
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance Canada
Find the latest Cognition Therapeutics, Inc. (CGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance
Discover historical prices for CGTX stock on Yahoo Finance. View daily, weekly or monthly format back to when Cognition Therapeutics, Inc. stock was issued.
Cognition Therapeutics, Inc. (CGTX) 股價、新聞、報價和記錄
查看最新的Cognition Therapeutics, Inc. (CGTX) 股票報價、記錄、新聞及其他重要資訊,助你賣買股票及投資。
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance
Interactive Chart for Cognition Therapeutics, Inc. (CGTX), analyze all the data with a huge range of indicators.
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call …
2024年10月9日 · Cognition Therapeutics Inc (NASDAQ:CGTX) reported a 39% slowing of cognitive decline in the SHINE trial for Alzheimer's disease, which is higher than the 25-30% seen with recently approved ...
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance
See the company profile for Cognition Therapeutics, Inc. (CGTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...
Cognition Therapeutics Announces Positive Results in Phase 2 …
PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline ...
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies …
2024年12月20日 · B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The company’s topline results from the Phase 2 SHIMMER study ...